Frontlight ResearchEarly access
TerminatedPhase 1
Phase I Study of the BBP-398 in Patients With Advance Solid Tumors
Key facts
- Who runs it
- LianBio LLC
- Where
- China2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 1
- People taking part
- 7 people enrolled
- Started
- 18 Oct 2022
- Ended
- 29 Mar 2024
- Type of study
- Interventional
- Treatments tested
- BBP-398
- Record updated
- 25 June 2024
- Why it stopped
- Business reason
Who can take part
- Age
- 18 years to 99 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Patients must have the ability to understand and the willingness to sign a written informed consent document 2 Patients must be willing and able to comply with the scheduled visits, treatment plan, laboratory tests and other specified study procedures 3. Age ≥18, male or female 4.Dose escalation: locally advanced or metastatic solid tumors Dose expansion: Advanced or metastatic EGFR-mutant NSCLC 5. Patients must have measurable disease by RECIST v1.1. 6. Patients must have an ECOG performance status (PS) ≤2 7.Patients with a life expectancy of ≥12 weeks. 8. Patients must have adequate organ function
Who cannot take part
- Patients who have previously received a SHP-2 inhibitor
- Treatment with any of the related anti-cancer therapies prior to the first dose of BBP-398 within the stated timeframes
- Patients with a history of CVA, myocardial infarction or unstable angina within the previous 6 months before starting therapy
- Patients with persisting toxicity related to prior therapy
- Patients who have undergone major surgery within 4 weeks prior to study enrollment
- Patients with a known additional malignancy that is progressing or requires active treatment
- Patients who are hypersensitivity to SHP-2 inhibitor or any ingredients
- Patients with known active Hepatitis B, Hepatitis C infection, or HIV infection
- Patients with any of the cardiac-related issues or findings
- Patients with inability to swallow oral medications or with gastrointestinal illness that would preclude the absorption of an oral agent
- Patients with known central nervous system (CNS) tumors
- Patients with known active CNS metastases and/or carcinomatous meningitis
- Pregnant or breastfeeding female patients
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is an open label, dose escalation and expansion, two-part Phase I study for SHP-2 inhibitor BBP-398 to evaluate the safety, tolerability, pharmacokinetics, determine MTD and/or RP2D, and preliminary anti- cancer activity in Chinese subjects with advanced solid tumors and in Chinese subjects with advanced or metastatic EGFR-mutant NSCLC.
The group in the trial
- Part A Dose Escalation and Part B Dose ExpansionTreatment being tested
Part A: Oral capsules taken in escalating levels to determine MTD/RP2D. Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD). Part B: Oral capsules administered at MTD/RP2D defined dose. Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD)
Treatment: BBP-398
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase I, Open Label, Dose Escalation and Expansion, Two- Part Study of SHP-2 Inhibitor BBP-398 to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-cancer Activity in Chinese Subjects With Advanced Solid Tumors
- Record updated
- 25 June 2024